This suggests that pharmacologic inhibition of TREM1, in patients with HIV and viral hepatitis coinfection, may be an attractive strategy to limit subsequent systemic and hepatic inflammation and the subsequent development of HCC. The gene discussed is TREM1; the disease is hepatocellular carcinoma.